Tudorza pressair approved for COPD

(HealthDay) -- The Tudorza Pressair (aclidinium bromide) inhaler has been approved by the U.S. Food and Drug Administration to treat narrowing of the lung airways associated with chronic obstructive pulmonary disease (COPD) in people 18 and older.

COPD, most often caused by smoking, encompasses chronic bronchitis and emphysema. Symptoms usually include , excessive phlegm and chest tightness, the FDA said in a news release.

The Tudorza Pressair inhaler, to be used twice daily, relaxes muscles around the lung's large airways, improving breathing. It is not meant to be used as a rescue inhaler during sudden asthma attacks, the agency said.

Common side effects observed during clinical testing included headache, nasal inflammation and cough.

The inhaler is distributed by St. Louis-based Forest Pharmaceuticals, a subsidiary of Forest Laboratories.

More information: Medline Plus has details about COPD.

add to favorites email to friend print save as pdf

Related Stories

Beta blockers may help COPD sufferers

May 12, 2011

(Medical Xpress) -- Beta blockers, the group of drugs commonly prescribed to patients with heart diseases, may also have considerable benefits for sufferers of diseases such as chronic bronchitis and emphysema, according ...

FDA phases out inhaler due to environmental impact

Sep 22, 2011

(AP) -- Asthma patients who rely on over-the-counter inhalers will need to switch to prescription-only alternatives as part of the federal government's latest attempt to protect the Earth's atmosphere.

Smokers' COPD risk is genetic

Mar 11, 2009

It's well known that puffing on cigarettes can eventually leave you out of puff. But why do a quarter of long-term smokers develop serious breathing problems, when others do not? New research published BioMed Central's open ...

New NIH data show gains in COPD awareness

Nov 09, 2010

The number of Americans who report being aware of chronic obstructive pulmonary disease, or COPD, increased by 4 percentage points between 2008 and 2010, but many people at risk are still unaware of the disease, according ...

Recommended for you

Ebola aid dogged by coordination lags in Guinea

1 hour ago

Eight months into West Africa's Ebola outbreak, aid efforts in Guinea still suffer from poor coordination, hampering deployments of international support to help quell a virus that has killed more than 1,200 ...

Long wait yet for Ebola vaccine: experts

6 hours ago

It will be months, at least, before a vaccine becomes available to tackle Ebola, experts said Thursday as researchers reported success in early, safety tests with a leading candidate.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.